About Nutcracker Therapeutics
Nutcracker Therapeutics is a company based in Emeryville (United States) founded in 2018 by Benjamin Eldridge and Igor Khandros.. Nutcracker Therapeutics has raised $227.04 million across 2 funding rounds from investors including Arch Venture Partners. Nutcracker Therapeutics offers products and services including RNA Therapeutics Platform. Nutcracker Therapeutics operates in a competitive market with competitors including Twist Bioscience, Nuclera Nucleics, Ansa Biotechnologies, DNA Script and Sensible Biotechnologies, among others.
- Headquarter Emeryville, United States
- Founders Benjamin Eldridge, Igor Khandros
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Nutcracker Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$227.04 M (USD)
in 2 rounds
-
Latest Funding Round
$167 M (USD), Series C
Mar 29, 2022
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nutcracker Therapeutics
Nutcracker Therapeutics offers a comprehensive portfolio of products and services, including RNA Therapeutics Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
End-to-end platform for RNA design, delivery, and manufacturing of treatments.
Unlock access to complete
Unlock access to complete
Funding Insights of Nutcracker Therapeutics
Nutcracker Therapeutics has successfully raised a total of $227.04M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $167 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series C — $167.0M
-
First Round
First Round
(18 May 2020)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2022 | Amount | Series C - Nutcracker Therapeutics | Valuation | Arch Venture Partners |
|
| May, 2020 | Amount | Series B - Nutcracker Therapeutics | Valuation | Arch Venture Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nutcracker Therapeutics
Nutcracker Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Arch Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nutcracker Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nutcracker Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nutcracker Therapeutics Comparisons
Competitors of Nutcracker Therapeutics
Nutcracker Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Twist Bioscience, Nuclera Nucleics, Ansa Biotechnologies, DNA Script and Sensible Biotechnologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
|
| domain | founded_year | HQ Location |
Desktop bioprinter for genes and proteins production is developed.
|
|
| domain | founded_year | HQ Location |
DNA synthesis technology using enzymes is provided.
|
|
| domain | founded_year | HQ Location |
Benchtop DNA printers for nucleic acid synthesis are developed.
|
|
| domain | founded_year | HQ Location |
Developer of mRNA technology for therapeutics and vaccines
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nutcracker Therapeutics
Frequently Asked Questions about Nutcracker Therapeutics
When was Nutcracker Therapeutics founded?
Nutcracker Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Nutcracker Therapeutics located?
Nutcracker Therapeutics is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Who is the current CEO of Nutcracker Therapeutics?
Igor Khandros is the current CEO of Nutcracker Therapeutics. They have also founded this company.
Is Nutcracker Therapeutics a funded company?
Nutcracker Therapeutics is a funded company, having raised a total of $227.04M across 2 funding rounds to date. The company's 1st funding round was a Series B of $60.04M, raised on May 18, 2020.
What does Nutcracker Therapeutics do?
Nutcracker Therapeutics was founded in 2018 and is based in Emeryville, United States. Proprietary technology is utilized to produce patient-specific mRNA therapeutics on single-use biochips within the biotechnology sector. Operations involve software-controlled automation for process management, rapid production cycles, and a library of delivery vehicles tailored to specific indications. This platform supports targeted therapeutic development.
Who are the top competitors of Nutcracker Therapeutics?
Nutcracker Therapeutics's top competitors include Nuclera Nucleics, Twist Bioscience and Ansa Biotechnologies.
What products or services does Nutcracker Therapeutics offer?
Nutcracker Therapeutics offers RNA Therapeutics Platform.
Who are Nutcracker Therapeutics's investors?
Nutcracker Therapeutics has 1 investor. Key investors include Arch Venture Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.